pharma · Cystic Fibrosis · Multiple Sclerosis · RARE
Ultragenyx UK
Ultragenyx UK Limited
Ultragenyx UK clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Newcastle upon tyne, NE128RL, GB, NOVATO, CA
- Founded
- 2024
- Employees
- 2
- Programs
- 201
- Drugs
- 168
- Patents
- 23
Ultragenyx UK projects
5 ClinicalTrials.gov programs sponsored by Ultragenyx UK.
Ultragenyx UK has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Crysvita (burosumab-twza) Treatment
Ultragenyx UK Limited
Epidermal Nevus Syndrome
1 trial -
Leucovorin calcium
Ultragenyx UK Limited
Toxoplasmosis
1 trial -
Osilodrostat (Isturisa)
Ultragenyx UK Limited
Mild Autonomous Cortisol Secretion (MACS)
1 trial -
epoprostenol
Ultragenyx UK Limited
Hypertension, Pulmonary
1 trial -
miglustat
Ultragenyx UK Limited
GM1 Gangliosidoses
1 trial
Frequently asked questions
How many clinical projects does Ultragenyx UK have?
5 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.